ERBB2 and colorectal carcinoma: Although, in TAPUR trial, pertuzumab plus trastuzumab cotreatment does not show an effective antitumor activity in CRC with HER2/3 mutations, CRC patients with HER2 amplification exhibited promising response rates to these drugs [41].